What Andrew Huberman has said about peptides and BPC-157

Andrew Huberman has covered peptides in three Huberman Lab episodes: a 2024 solo episode, a 2024 interview with Dr. Craig Koniver and a 2026 interview with Dr. Abud Bakri. His repeated points: BPC-157 evidence in people is thin, black and gray market products may be contaminated, and anyone with a cancer concern should be cautious (Huberman Lab). None of it is medical advice or changes legal status.

Below we summarize each episode in our own words from the official episode pages, list the cautions he gave, and set them against the published evidence and the HHS interim policy of 28 October 2026. We do not repeat any doses or protocols discussed on the show; a prescriber sets those. Listing here is not an endorsement by or of anyone named.

The three Huberman Lab peptide episodes

Dates and topics come from each episode's page on hubermanlab.com, read on 30 October 2026. The pages carry transcripts marked as under human review, so wording may still change.

What Huberman said about BPC-157

In the 2024 solo episode, Huberman described BPC-157 as a lab-made peptide modeled on one found in the gut, and said most of what is known comes from preclinical research going back to the early 1990s. He said he knew of only one human study, that it was not a clinical trial, and that it was poorly done. He described the human reports as anecdotal: many users say injuries healed faster, but there was essentially no controlled human data.

His main safety caution was about blood vessel growth. BPC-157 is thought to promote new blood vessels at injury sites, and he reasoned that the same effect could feed a tumor. In his words, "BPC-157 is a potential tumor growth risk." (Huberman Lab, solo episode). He told listeners with a cancer history or concern to be very cautious, and said he was not suggesting anyone start taking it. That is a reasoned concern from mechanism, not a finding from a human trial.

What he said about sourcing and quality

Sourcing came up in all three episodes. In the solo episode Huberman sorted peptides into three groups: those prescribed by physicians, a gray market sold online, and a black market. He said he does not suggest black market peptides and that many are contaminated, and he singled out bacterial endotoxin (lipopolysaccharide) as a contaminant that may build up with repeated exposure.

In the Koniver interview he returned to the point, saying he worried that "people are buying BPC from dark gray market or black market sources" (Huberman Lab, Koniver episode). He and Koniver contrasted those sellers with licensed compounding pharmacies, and Koniver described pharmacies as regulated by state boards and tested for purity. Both said people should work with a physician.

In the 2026 Bakri interview, Huberman asked about products labeled for research only and summed up the answer: "So it is risky to get for research purposes only peptides." (Huberman Lab, Bakri episode). Bakri said quality varies from batch to batch and that compounding pharmacies also vary in how well they test. Our guide to research peptides vs prescription peptides covers what FDA has said about those sellers.

What he and his guests said about legality

The legal picture changed between episodes, and each conversation reflects its date:

• October 2024 (Koniver): both described BPC-157 as effectively removed from the legitimate market after FDA placed it on its category 2 list, so licensed pharmacies could no longer compound it. Koniver dated that to October 2023; the HHS policy itself says BPC-157 was in category 2 from September 2023 until April 22, 2026.
• June 2026 (Bakri): Bakri said BPC-157 had never been FDA-approved, had been removed from category 2 in April 2026 but was not yet on category 1, and that state medical boards could still restrict it. He also said a doctor who prescribes an unapproved peptide carries malpractice risk.

One correction for listeners: in the solo episode Huberman described sermorelin as FDA-approved. Its brand product was withdrawn years ago, and sermorelin is not FDA-approved today; see our sermorelin FDA status guide.

How it compares with the evidence today

Huberman's 2024 point that human data are thin still holds. A 2026 systematic review found three human studies with 30 participants in total, judged all of them poor quality and concluded that "Overall certainty of evidence was rated very low due to serious risk of bias, indirectness and imprecision" (Poolton et al. 2026, PubMed 42885452). A 2025 review of 36 studies found 35 preclinical and one clinical, and reported "No clinical safety data were found" (Vasireddi et al. 2025, PubMed 40756949). The tumor concern he raised has not been tested in a human trial either way. Our BPC-157 side effects guide has the detail.

Where the rules stand now (checked 30 October 2026)

On 28 October 2026 HHS issued an interim policy saying it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A" (Federal Register 2026-22192). Appendix A lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Several peptides discussed on the show, including ipamorelin, CJC-1295, GHK-Cu injections and thymosin alpha-1, are not on it.

The same notice says "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed" and that HHS "may revisit application of this interim policy" if a safety or quality problem arises (Federal Register). It is not FDA approval, it can be withdrawn, and it does not bind state boards. Our HHS peptide policy guide and BPC-157 legal status guide explain the conditions.

Other public voices

The policy was signed by HHS Secretary Robert F. Kennedy Jr. Earlier, in a Joe Rogan Experience episode that aired in late February 2026, Kennedy said he wanted the peptides moved to where people could get them from ethical suppliers and acknowledged the research was incomplete, as reported by Gizmodo on 2 March 2026. We could not read a primary transcript of that episode, so we do not quote it. We found no on-the-record statement on BPC-157 from Peter Attia that we could verify, so we leave him out.

What this means if you are considering BPC-157

The cautions on the show line up with what a careful buyer would check anyway: a licensed prescriber who screens you, a named state-licensed pharmacy, and no research-use-only vials. Prescription programs for BPC-157 on this site start at $149 a month; see all BPC-157 prices and our BPC-157 overview. If you have a cancer history, raise it with the prescriber first, as Huberman suggested.

FAQ

What has Andrew Huberman said about peptides?

Huberman has covered peptides in a 2024 solo episode and in interviews with Dr. Craig Koniver (2024) and Dr. Abud Bakri (2026). He described their biology, said evidence in people is limited for many of them, warned that black and gray market products may be contaminated, and urged listeners to work with a physician. He also said he was not suggesting anyone start taking them.

What did Huberman say about BPC-157?

Huberman said most BPC-157 data are preclinical, that he knew of only one weak human study in 2024, and that user reports are anecdotal. His main caution was that BPC-157 may promote blood vessel growth and so could be a tumor growth risk. He told people with cancer concerns to be very cautious about using it.

Does Huberman take BPC-157 or recommend it?

Huberman said in the 2024 solo episode that he was not suggesting anyone run out and take BPC-157, and framed the episode as information for making a personal decision. We found no statement on the official episode pages endorsing a product or seller. Any decision belongs with a licensed prescriber who knows your history.

Is BPC-157 legal now?

BPC-157 is not FDA-approved. Since 28 October 2026, an interim HHS policy says the agency does not intend to take enforcement action against state-licensed 503A pharmacies compounding it on a prescription, under strict conditions. The policy can be withdrawn, does not bind states, and excludes blends. Status checked 30 October 2026; see our legal status guide.

Did Huberman warn about research peptides?

Yes. Huberman warned in all three episodes about gray and black market sources, including products labeled for research use only. He said many are contaminated and singled out endotoxin. In the 2026 episode he concluded that buying research-only peptides is risky, and his guest said quality varies batch to batch.

Is there human evidence for BPC-157?

Very little. A 2026 systematic review found three human studies with 30 people in total, rated all of them poor quality and judged the certainty of evidence very low. A 2025 review found one clinical study among 36 and no clinical safety data. Larger controlled trials have not been published.

Compare licensed prescription programs on price, labs and oversight on our best peptide programs page, or see every plan on the price table.